Microsatellite Instability-High (MSI-H) and Mismatch Repair (MMR) are two critical concepts in the field of oncology. To understand them, think of your DNA as a long, complex sentence. This sentence is constantly being copied within your cells, and sometimes, mistakes or "typos" occur during this copying process. These "typos" in the DNA sequence are what we refer to as microsatellites.
MSI-H refers to a condition where these "typos" become frequent and the DNA sequences become unstable. On the other hand, MMR is like the body's personal proofreader. It's a system within our cells that corrects these "typos" to maintain the stability and integrity of our DNA.
When the MMR system fails or is deficient, it can lead to MSI-H. This is akin to having a proofreader who's fallen asleep on the job, allowing the "typos" to accumulate. This instability in the DNA sequences can result in mutations that promote cancer growth.
The MMR system plays a crucial role in preventing cancer by maintaining the integrity of our DNA. However, when this system is deficient, it can lead to the development of MSI-H, increasing the risk of cancer.
MSI or MMR testing is recommended for all types of colorectal cancer. However, it can also be beneficial for other types of cancer, given the role of MSI-H/MMR in cancer development.
Testing for MSI can be done through two main methods: immunology and genetic testing.
Immunology testing involves examining the proteins produced by the MMR genes. If these proteins are absent or not functioning correctly, it can indicate a problem with the MMR system.
Genetic testing, on the other hand, looks directly at the DNA. It checks for specific changes or mutations in the MMR genes that can lead to a deficiency in the MMR system.
If you are a cancer patient, you can request MSI-H/MMR testing from your oncologist. This test is also done as a part of Next-Generation tumor sequencing, which can be ordered by your oncologist. This comprehensive test can provide valuable information about the genetic makeup of your tumor, including your MSI-H/MMR status.
Patients with MSI-H tumors often have a better prognosis than patients with Microsatellite Stable (MSS) tumors. This is because MSI-H tumors often have a higher mutational load, which can make them more responsive to certain treatments.
MSI-H/MMR status can also influence a patient's response to treatment. For instance, MSI-H/MMR deficient tumors have been found to respond well to immunotherapy, a type of treatment that boosts the body's natural defenses to fight cancer.
Traditional cancer treatments such as chemotherapy and radiation therapy can be effective for many patients. However, the effectiveness of these treatments can vary depending on the patient's MSI-H/MMR status.
Immunotherapy has emerged as a promising treatment option for patients with MSI-H/MMR deficient tumors. This is because these tumors often have a high mutational load, which can make them more visible to the immune system.
MSI-H and MMR are being used in many clinical trials to explore new treatment options for cancer patients. These trials are not limited to colorectal cancer but extend to various other types of cancer as well. The goal is to find more effective treatments that can improve the prognosis and quality of life for cancer patients.
A recent clinical trial involving 18 rectal cancer patients demonstrated the potential of MSI-H/MMR testing in transforming cancer treatment. In this trial, every patient was given a drug called dostarlimab, a type of checkpoint inhibitor, as the first line of treatment instead of surgery, chemotherapy, and radiation. Astonishingly, the cancer vanished in every single patient, undetectable by physical exam, endoscopy, PET scans, or MRI scans. This unexpected result has sparked hope and excitement in the field of oncology, highlighting the potential of MSI-H/MMR testing in improving cancer treatment outcomes.
Deficiencies in DNA mismatch repair (dMMR) can be caused by hereditary, germline mutations. This means that individuals with a family history of certain cancers may have an increased risk of developing MSI-H/MMR deficient tumors. Family members of patients with these types of tumors can also be tested for MSI-H/MMR. If they test positive, they may need to undergo heightened cancer screening to detect any potential cancers early.
Understanding MSI-H/MMR is crucial for cancer patients as it can influence prognosis, treatment response, and even hereditary risk. By staying informed, patients can better navigate their treatment options and make more informed decisions about their care.
Most patients are handed a treatment plan and told to begin. But what if there are better options—or steps being missed?
This free 5-day email series helps you understand the hidden opportunities that could shape your care. It covers what many patients wish they had known sooner—before key decisions were made.
You’ll get insights on:
Each short email builds on the last, helping you feel more informed and in control—right when decisions matter most.
Join hundreds of patients gaining clarity and confidence—in just 5 short emails.
